

CNMV Edison, 4 28006 Madrid

Barcelona (Spain), 23 de julio de 2020

OTHER RELEVANT INFORMATION

In accordance with the Article 227 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, **LABORATORIO REIG JOFRE SA** ("Reig Jofre" or "the Company"), informs that the Ordinary and Extraordinary General Shareholders' Meeting was held upon the first call on April 25, 2019, with the agenda established and present shareholders owning 82,0855 % of the share capital.

All resolutions were adopted by the legal and statutory majorities, being the following:

- The individual and consolidated financial statements and the individual and consolidated management reports, the allocation of result obtained by the individual company during the year (€ 2,825,390.38) to the provision of voluntary reserves and the conduct of business of the board of directors, all of that regarding the year 2019.
- 2. The appointment of new members of the company's Board of Directors.
- 3. The re-election of "KPMG Auditores, SL" as the auditors of the Company and its consolidated Group for the next three years (2020, 2021 and 2022).
- 4. The Annual Report on the Remuneration of the Directors of the Company corresponding to 2019, with a consultative vote.
- 5. The amendment to the Board of Directors Regulation in order to limit to four the number of Boards of other companies of which a member of the Company's Board may form part.



- 6. Within "Reig Jofre Flexible Dividend" plan, an increase in the Company's share capital with a charge to reserves for an amount determined in accordance with the terms of the agreement, through the issuance of new ordinary shares with a nominal value of fifty cents and with provision for incomplete allocation. Offer to shareholders for the purchase of their free allocation rights for a guaranteed price. Request for admission to trading of issued shares. Delegation of powers to the Board of Directors, with express power of substitution, for the specification of the details concerning said capital increase. The sum of the reference market value of the New Shares, in accordance with the agreement, will have a maximum limit of € 3,042,498.28.
- 7. The modification of the Company's Bylaws, relating to the Company's corporate purpose, in order to include within the corporate purpose the provision of marketing and product promotion services.
- 8. For the call of extraordinary shareholders' meetings, up to the celebration of the next Ordinary General Shareholders Meeting, the applicable term be fifteen days.
- 9. The board of directors, with express power of substitution, were granted powers for the formalization, interpretation, correction and/or implementation of the agreements adopted by the General Shareholders Meeting.

Yours faithfully,

Adolf Rousaud Secretary of the Board of Directors Laboratorio Reig Jofre SA